Is MiMedx Group, Inc. (MDXG)’s Fuel Running Low? The Stock Just Declined Again

February 25, 2018 - By Louis Casey

Investors sentiment decreased to 1.97 in Q3 2017. Its down 0.05, from 2.02 in 2017Q2. It fall, as 21 investors sold MiMedx Group, Inc. shares while 44 reduced holdings. 48 funds opened positions while 80 raised stakes. 77.22 million shares or 15.28% more from 66.99 million shares in 2017Q2 were reported.
Moreover, Voloridge Investment Ltd Liability Company has 0.11% invested in MiMedx Group, Inc. (NASDAQ:MDXG) for 417,278 shares. Metropolitan Life Ins New York owns 69,927 shares for 0.01% of their portfolio. Yorktown Mngmt And Rech Incorporated, a Virginia-based fund reported 26,500 shares. 48,732 are owned by Cornerstone Capital Mgmt Ltd Liability Co. Aperio Gp Ltd stated it has 0% of its portfolio in MiMedx Group, Inc. (NASDAQ:MDXG). Citigroup reported 0% of its portfolio in MiMedx Group, Inc. (NASDAQ:MDXG). Ls Investment Limited Liability holds 0.02% or 23,992 shares in its portfolio. Moreover, Thompson Davis & has 0.03% invested in MiMedx Group, Inc. (NASDAQ:MDXG) for 1,500 shares. Blackrock Incorporated reported 0.01% in MiMedx Group, Inc. (NASDAQ:MDXG). Gotham Asset Mngmt has 1.05M shares for 0.18% of their portfolio. 7.56M are held by Vanguard Gp. Natixis has 14,845 shares for 0% of their portfolio. Cutter & Brokerage Incorporated reported 0.08% of its portfolio in MiMedx Group, Inc. (NASDAQ:MDXG). 150,000 were accumulated by Deerfield Co. Rowland And Inv Counsel Adv invested 1.29% of its portfolio in MiMedx Group, Inc. (NASDAQ:MDXG).

The stock of MiMedx Group, Inc. (NASDAQ:MDXG) is a huge mover today! The stock decreased 11.82% or $1.05 during the last trading session, reaching $7.83. About 14.09 million shares traded or 444.06% up from the average. MiMedx Group, Inc. (NASDAQ:MDXG) has risen 107.87% since February 25, 2017 and is uptrending. It has outperformed by 91.17% the S&P500.
The move comes after 5 months negative chart setup for the $869.40M company. It was reported on Feb, 25 by We have $7.13 PT which if reached, will make NASDAQ:MDXG worth $78.25M less.

MiMedx Group, Inc. (NASDAQ:MDXG) Ratings Coverage

Among 8 analysts covering MiMedx Group (NASDAQ:MDXG), 5 have Buy rating, 2 Sell and 1 Hold. Therefore 63% are positive. MiMedx Group had 28 analyst reports since July 29, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, January 18 by Needham. The firm has “Underweight” rating given on Tuesday, May 23 by First Analysis. Needham maintained the shares of MDXG in report on Friday, December 1 with “Buy” rating. The firm has “Buy” rating given on Thursday, July 27 by Needham. The firm earned “Buy” rating on Wednesday, October 14 by Needham. The company was maintained on Monday, June 26 by Needham. The rating was maintained by Lake Street on Tuesday, April 19 with “Buy”. The rating was maintained by Piper Jaffray on Thursday, July 13 with “Buy”. The stock has “Buy” rating by Piper Jaffray on Friday, August 18. The rating was maintained by Needham on Tuesday, October 10 with “Buy”.

More notable recent MiMedx Group, Inc. (NASDAQ:MDXG) news were published by: which released: “Why MiMedx Group Inc. Shares Are Falling Again” on February 23, 2018, also with their article: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” published on February 20, 2018, published: “Wolf Popper LLP Announces Investigation on Behalf of Investors in MiMedx Group …” on February 20, 2018. More interesting news about MiMedx Group, Inc. (NASDAQ:MDXG) were released by: and their article: “MiMedx: Do The Numbers Support Channel Stuffing Accusations?” published on February 22, 2018 as well as‘s news article titled: “RM LAW Announces Investigation of MiMedx Group, Inc.” with publication date: February 20, 2018.

MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. The company has market cap of $869.40 million. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. It has a 25.18 P/E ratio. The companyÂ’s proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: